Meeting
2023 ASCO Annual Meeting
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.
Authors
Min Yan
Department of Breast Disease, Henan Breast Cancer Center. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
Min Yan , Quchang Ouyang , Tao Sun , Limin Niu , Jin Yang , Li Li , Yuhua Song , Chunfang Hao , Zhanhong Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT03691051
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1048)
DOI
10.1200/JCO.2023.41.16_suppl.1048
Abstract #
1048
Poster Bd #
269
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
First Author: Min Yan
Poster
2022 ASCO Annual Meeting
Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.
First Author: Xiuwen Guan
Poster
2022 ASCO Annual Meeting
Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
First Author: Ian E. Krop
Poster
2021 ASCO Annual Meeting
Real-world outcomes of breast cancer patients with brain metastases treated with radiotherapy in Ontario: A population-based study.
First Author: Katarzyna Joanna Jerzak